97 results
Page 2 of 5
8-K
EX-99.1
m4sl3m
13 Sep 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9:59pm
8-K
EX-99.2
psxfj
13 Sep 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9:59pm
8-K
EX-99.1
x1upqjydo3k rep1pj4
8 Sep 22
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
4:02pm
8-K
EX-99.1
6lyt 4a5r6o2aes0buo
26 Aug 22
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
5:30pm
8-K
EX-99.1
91e rz7qk3dcv6umsf
10 Aug 22
InMed Announces Changes to its Board of Directors
8:12pm
8-K
EX-99.1
ddcgo51v
26 Jul 22
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
1:32pm
8-K
EX-99.1
1v8p255vbv9
19 Jul 22
InMed Announces Appointment of Chief Operating Officer
7:43pm
424B3
xh3 ylizwe
6 Jul 22
Prospectus supplement
2:43pm
8-K
EX-99.1
8ryu7n br3lq
15 Jun 22
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential
6:04pm
8-K
EX-99.1
4nbmbvpgca ja4
10 Jun 22
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
4:36pm
8-K
EX-99.1
9ey5bd yun0xvngr
6 Jun 22
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
9:47pm
8-K
EX-99.1
qubhtn0x awo0jtbz
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
424B5
e39jrfpd
3 Jun 22
Prospectus supplement for primary offering
9:45pm
8-K
EX-99.1
7hk qa9bve
18 May 22
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
1:34pm
8-K
EX-99.1
w5f7rc rxd
6 May 22
Regulation FD Disclosure
2:50pm
8-K
EX-99.1
1qpwu6rv9cg6
28 Apr 22
Regulation FD Disclosure
2:35pm
424B3
3kcia2x2
25 Apr 22
Prospectus supplement
5:02pm
8-K
EX-99.1
2b7t yiey0lx12
21 Apr 22
Regulation FD Disclosure
2:46pm